News and Announcements
Sun Biomedical Tapping into US$11B Kidney Disease Sector
- Published June 30, 2015 3:37PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
June 30th 2015 by Proactive Investors
Sun Biomedical (ASX:SBN) is proceeding with the acquisition of platform drug discovery and clinical stage biotechnology company Dimerix Bioscience after satisfying all conditions precedent.
The transaction is now unconditional and should be completed by the close of business on 3rd July 2015.
Dimerix is currently recruiting in to Phase 2 clinical study for its lead therapeutic product DMX200 that is targeted at patients with chronic kidney disease (CKD).
CKD affects over 26 million people in the U.S. alone. The market in exceeds $11 billion in sales per annum and continues to grow.
Dimerix’s initial strategy is to pursue an orphan indication, Nephrotic Syndrome, and subsequently partner the development of programs in larger disease indications.
It is engaged in research collaborations with top pharmaceutical companies using its proprietary GPCR (G protein coupled receptors) drug discovery platform.
To read the full story, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
